Origin & tradition
Not traditional: PS supplementation emerged from neuroscience; originally derived from bovine brain, now from sunflower/soy.
Western tradition · Phospholipid
The structural phospholipid of neuronal membranes — the only supplement with an FDA-qualified health claim for cognitive function.
↑ iHerb link is an affiliate link — we may earn a commission at no cost to you.
Not traditional: PS supplementation emerged from neuroscience; originally derived from bovine brain, now from sunflower/soy.
Key active: Phosphatidylserine (phospholipid — sunflower or soy-derived).
PS is the predominant phospholipid in neuronal inner membranes, critical for PKC and Akt signaling. Brain PS declines with age. Over 900 subjects in published RCTs show modest-to-moderate benefits for age-associated memory impairment, leading to an FDA qualified health claim: 'may reduce the risk of dementia and cognitive dysfunction in the elderly.'
Effect summary
| Health outcome | Effect | Magnitude | Grade |
|---|---|---|---|
| Cognitive function / memory (elderly) | Increases | Moderate | B |
| Working memory | Increases | Moderate | B |
| Cortisol response to exercise | Decreases | Moderate | B |
| Attention (children with ADHD) | Increases | Moderate | B |
| Alzheimer's symptoms (mild) | Decreases | Minor | C |
Grade: A = robust RCTs · B = several RCTs / meta-analysis · C = limited or mixed RCTs · D = observational or early data
Dosage guidance
The FDA allows a qualified health claim for PS and cognitive dysfunction. Soy-derived and sunflower-derived PS are both effective. Sharp-PS is a common branded form studied in clinical trials.
Informational only — not a prescription or personalised medical advice. Consult a qualified clinician before starting any supplement or medication.
Evidence summary
Multiple RCTs (memory, cognition); FDA qualified health claim
PS is the predominant phospholipid in neuronal inner membranes, critical for PKC and Akt signaling. Brain PS declines with age. Over 900 subjects in published RCTs show modest-to-moderate benefits for age-associated memory impairment, leading to an FDA qualified health claim: 'may reduce the risk of dementia and cognitive dysfunction in the elderly.'
According to PubMed and ClinicalTrials.gov: trial counts from ClinicalTrials.gov, peer-reviewed literature from PubMed. Counts auto-refresh weekly; last checked 2026-06-12. They include trials across many endpoints, not only longevity.
Informational only — not medical advice, a treatment claim, or a substitute for a qualified clinician. Evidence strength varies; we show mixed and null results on purpose.
Evidence collections
Suppliers
Tell us what you need and we will source suppliers for you.